GuidelineCurrent
Global Candidiasis 2025 — Global guideline for the diagnosis and management of candidiasis
ECMM/ISHAM/ASM, 2025
Use susceptibility- and host-informed therapy for invasive candidiasis, with echinocandins remaining preferred initial therapy for many critically ill adults, prompt source control, follow-up cultures, and individualized step-down once clinically stable and an active oral agent is available.
Conditional recommendationModerate certainty
View source guidelineClinical Context & Relevant Topics (2)
Disease ReferenceCandidemia & Invasive Candidiasis
ICU recognition and treatment of candidemia and invasive candidiasis, including source control, repeat cultures, step-down therapy and metastatic infection.
View Topic Context →
Immunocompromised & Oncologic Critical Illness
Host immune defects, neutropenic sepsis, acute respiratory failure (PJP/Aspergillus), tumor lysis syndrome, leukostasis, CAR-T CRS/ICANS, and ICU triage.
View Topic Context →